Compare American Airlines Group Inc (AAL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Airlines Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? American Airlines Group Inc trades at $16.3 (market cap $11.38B), while State Street SPDR S&P Biotech ETF trades at $160.84. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, American Airlines Group Inc nearer its low. Which is the better fit depends on your goals.
| AAL | XBI | |
|---|---|---|
Market Cap | $11.38B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $18.15 | $163.87 |
52-Week Low | $10.18 | $84.71 |
Enterprise Value | $38.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Airlines (AAL) trades at $17.20, down 4.02% amid sector rotation. The stock shows a bullish technical signal with strong moving average alignment, though RSI levels are mixed. Fundamentally, revenue grew to $54.63B in 2025, but net income fell sharply to $111M, reflecting margin pressure. Recent news highlights airline sector volatility, with fuel cost declines offering relief but broader market sentiment weighing on travel stocks.
Outlook remains cautious; analyst consensus is split with a $19.96 price target suggesting modest upside. Key risks include volatile fuel prices, competitive pressures, and high debt levels. Earnings consistency is critical for sustained recovery, with Q2 2026 results pivotal for confirming operational improvements.
XBI trades at $160.81, up 0.22% for the day, with a bullish technical signal driven by moving averages but overbought RSI readings. The ETF has surged approximately 17% over the past month, fueled by biotech sector momentum, AI-driven drug discovery advancements, and robust M&A activity. Analyst consensus remains neutral with a single hold rating, while recent news highlights strong performance relative to broader healthcare ETFs.
Outlook: XBI offers exposure to biotech growth catalysts including M&A and innovation, but high volatility and overbought conditions pose near-term risks. Long-term potential hinges on sector stability and pipeline successes, though investors face elevated beta and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
